Market Samachar
STAT
·
GLOBAL
·
Revolution Medicines starts shipping experimental pancreatic cancer drug - statnews.com
As reported by STAT
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
▸ MARKET SAMACHAR VIEW
NEUTRAL
Read full article on STAT ↗
Market Samachar is a news aggregator. This article was originally published by
STAT. Tap the button above to read the full story on their site.
🔥 Hot Now
Top stories across markets in the last hour
More from Market Samachar